Regulatory affairs teams in medtech and pharma face a convergence of deadlines in 2026 and 2027: EU MDR transition milestones, EUDAMED mandatory registration, the EU AI Act for high-risk devices, the Cyber Resilience Act, and the FDA's QMSR transition. Keeping up with these changes manually means reading hundreds of pages across multiple health authorities every month. A regulatory intelligence tool should make that unnecessary, but not all tools deliver the same value.
This guide provides five criteria you can use to evaluate any regulatory intelligence platform, whether you are selecting your first tool or replacing an existing one.
Criterion 1: Source coverage and jurisdiction depth
The most important question is what the tool actually covers. A platform that monitors only FDA guidance will leave gaps for teams working across multiple markets. Evaluate coverage across three dimensions:
Health authorities: At minimum, a useful tool should cover FDA, EMA, and the major national competent authorities (Swissmedic, MHRA, Health Canada, TGA, PMDA). For pharma teams, ICH guidelines and national pharmacopoeia references are equally important.
Document types: Guidance documents alone are not enough. Your tool should cover the full regulatory text (regulations, directives, implementing acts), MDCG guidance, harmonised standards references, Federal Register notices, safety communications, and inspection-related publications.
Depth of content: Some tools provide summaries or abstracts. Others link to the original source without full-text access. The most useful tools let you search within the actual regulatory text and return answers with direct citations to specific articles, sections, or paragraphs.
| Coverage level | What you get | Limitation |
|---|---|---|
| Headlines only | Notification that a document was published | No context, requires manual reading |
| Summaries | Third-party interpretation of the document | May miss nuances, not citable in submissions |
| Full-text indexed | Search within the actual regulatory language | Requires good search quality (see Criterion 2) |
| Full-text with citations | Answers linked to specific articles and sections | Best for regulatory writing and audit preparation |
Ask your vendor: "Can I search within the full text of EU MDR 2017/745 and get an answer citing a specific article?" If the answer is no, you are getting a news feed, not a regulatory intelligence tool.
Criterion 2: Search quality and answer relevance
Coverage is useless if you cannot find what you need. The search experience separates tools that save time from tools that create more work.
Keyword search returns every document containing your search terms. For regulatory databases with thousands of documents, this produces hundreds of results that you must read through manually.
Semantic search understands the meaning behind your query. Asking "What clinical evidence do I need for a Class IIa device under MDR?" should return the relevant sections of MDR Annex XIV and applicable MDCG guidance, not every document that mentions "clinical" and "Class IIa."
Cited answers go further by synthesising information from multiple sources and presenting a direct answer with linked citations. This lets you verify the answer against the original text and use the citations in your own documentation.
Evaluate search quality by testing with real questions your team asks regularly:
- "What are the GSPR requirements for software as a medical device?"
- "When does the EUDAMED vigilance module become mandatory?"
- "What post-market surveillance data must be included in a PSUR for a Class IIb device?"
- "What CMC documentation does FDA expect for a biosimilar BLA?"
If the tool cannot answer these directly, it is a document repository with a search bar, not an intelligence tool.
Criterion 3: Update speed and alert relevance
Regulatory landscapes change constantly. A tool that updates weekly will miss time-sensitive developments like draft guidance comment periods (often 60 to 90 days) or safety communications requiring immediate action.
Real-time monitoring means the tool detects new publications within hours of release, not days. This matters most for vigilance, field safety notices, and draft guidance with limited comment windows.
Configurable alerts let you filter by jurisdiction, topic, device class, or therapeutic area. A regulatory affairs manager responsible for EU MDR Class IIb devices should not receive alerts about FDA food safety recalls.
Signal versus noise: The best tools distinguish between routine updates and material changes that require action. A new MDCG guidance document on clinical evaluation is material. A minor formatting update to an existing webpage is not.
| Alert quality | Behaviour | Impact on your team |
|---|---|---|
| Unfiltered feed | Every publication from every authority | Information overload, critical items buried |
| Keyword alerts | Matches on terms you define | Better, but still noisy with false positives |
| Topic-aware alerts | Understands regulatory context and relevance | Actionable, reduces time spent filtering |
Criterion 4: Cross-referencing and regulatory context
Regulations do not exist in isolation. MDR references harmonised standards. MDCG guidance interprets specific MDR articles. FDA guidance cross-references CFR sections. A useful tool connects these relationships so you can navigate from a requirement to its interpretation and back.
Cross-referencing means that when you read MDR Article 61 on clinical evaluation, the tool surfaces the related MDCG guidance (2020-5, 2020-6, 2020-13), the applicable harmonised standards (ISO 14155 for clinical investigations), and any recent updates or corrigenda.
Regulatory context means understanding how a specific requirement fits into the broader framework. If you are researching post-market surveillance, the tool should connect PMS plan requirements (Article 84) to PSUR obligations (Article 86), to vigilance reporting (Articles 87-92), to the clinical evaluation update cycle (Article 61(11)).
This capability is particularly valuable for teams working across jurisdictions. Understanding how FDA QMSR requirements map to ISO 13485 clauses, or how EU AI Act obligations layer on top of MDR, requires a tool that can navigate these relationships.
Criterion 5: Practical workflow integration
A regulatory intelligence tool must fit into how your team actually works. Evaluate the following:
Accessibility: Can the tool be used by anyone on the regulatory affairs team without specialised training? Complex interfaces with steep learning curves reduce adoption and create bottlenecks around the one person who knows how to use the system.
Output quality: Can you use the tool's output directly in your work? Answers with proper citations can be pasted into technical documentation, audit responses, or regulatory submissions. Summaries without citations require additional verification work.
Collaboration: Can team members share findings, save searches, or build collections of relevant regulatory content for specific projects or submissions?
Multi-language support: For teams working across the EU, content in local languages (German, French, Italian, Spanish) is valuable for communicating with national competent authorities and for local labelling requirements.
Evaluation checklist
Use this checklist when assessing any regulatory intelligence platform:
Source coverage
- Covers FDA, EMA, and at least 3 additional national authorities
- Includes full regulatory text, not just guidance summaries
- Covers MDCG guidance, harmonised standards references, and ICH guidelines
- Includes pharma-relevant content (CMC guidance, pharmacopoeia, ICH CTD)
Search quality
- Returns direct answers to regulatory questions, not just document lists
- Provides citations to specific articles, sections, or paragraphs
- Handles natural language queries (not just keyword matching)
Update speed
- Detects new publications within hours, not days
- Offers configurable alerts by jurisdiction, topic, or device class
- Distinguishes material changes from routine updates
Cross-referencing
- Links regulations to related guidance and standards
- Connects requirements across jurisdictions
- Surfaces related documents when viewing a specific article
Workflow integration
- Usable without specialised training
- Output includes proper citations suitable for regulatory documentation
- Supports multiple languages relevant to your markets
Questions to ask any vendor
- "Show me how your tool answers a specific regulatory question with citations to the source text."
- "Which health authorities do you cover, and what document types are included for each?"
- "How quickly do new publications appear in your system after release?"
- "Can I search across multiple jurisdictions in a single query?"
- "How do you handle cross-references between regulations, guidance, and standards?"
- "What happens when I ask a question your database cannot answer?"
The answers to these questions will reveal whether you are evaluating a true regulatory intelligence tool or a document management system with a search bar.
Key takeaways
- Evaluate regulatory intelligence tools on five criteria: source coverage, search quality, update speed, cross-referencing, and workflow integration
- Full-text coverage with cited answers is significantly more valuable than headline monitoring or document summaries
- Test any tool with real regulatory questions your team asks daily before committing
- Cross-referencing between regulations, guidance, and standards saves the most time for regulatory affairs professionals
- The best tool is the one your team actually uses, so accessibility and output quality matter as much as database size
How RegAid helps
RegAid provides full-text regulatory intelligence across FDA, EMA, Swissmedic, and additional authorities, covering regulations, MDCG guidance, harmonised standards, and ICH guidelines for both medtech and pharma. Ask any regulatory question in natural language and get a cited answer linking to the specific article or section. Try it with your own questions at regaid.ch.